HARP News and Press, Harpoon Therapeutics Inc. From 08/10/22

Harpoon Therapeutics press release ( NASDAQ: HARP ): Q2 GAAP EPS of -$0.53 beats by $0.03 . Revenue of $8.3M (+43.1% Y/Y) beats by $1.34M . For further details see: Harpoon Therapeutics GAAP EPS of -$0.53 beats by $0.03, revenue of $8.3M beats by $1.34M ...

Presented encouraging interim data for anti-DLL3 T cell engager HPN328 from ongoing dose escalation clinical trial at the 2022 ASCO Annual Meeting Portfolio prioritization and resource alignment strengthens support for the advancement of HPN328, HPN217 and HPN601 SOUTH SAN...

Harpoon Therapeutics has an intriguing platform that can generate stable bispecific immunotherapies using their TriTAC technology. Their “off-the-shelf” T-cell engagers help T-cells eliminate solid tumors and hematologic cancers. The company has several catalysts for its...

Canaccord analyst William Maughan assumed coverage of Harpoon Therapeutics ( HARP ) with a Buy rating and $16 price target. Bispecific T-cell engagers, like the ones Harpoon is developing, are "among the hottest therapeutic strategies in development for oncology," said Maughan, wh...

Appointments named for two key executive leadership positions in human resources and translational medicine SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engage...

Companies focused on a class of drugs known as T-cell engagers are trading higher Tuesday after AstraZeneca ( NASDAQ: AZN ) announced an agreement to acquire the U.S.-based TeneoTwo for a total consideration of up to $1.3B. The acquisition will further diversify its hema...

Clinically active and well tolerated in patients with solid tumors Favorable safety profile emerging: 22% of patients experienced Grade 1-2 cytokine release syndrome (CRS); no Grade 3 or higher CRS One confirmed partial response; 27% of small cell lung cancer (SCLC) patients with ...

3 Penny Stocks to Add to Your Watchlist This Week With another interesting week of trading penny stocks off to a relatively flat start, there is a lot that investors need to know. For starters, making money with penny stocks is all about understanding exactly where to look to find t...

Gainers: Data Storage Corporation (DTST) +40%. Indonesia Energy Corporation (INDO) +30%. Harpoon Therapeutics (HARP) +28%. Pulse Biosciences (PLSE) +24%. Praxis Precision Medicines (PRAX) +24%. Xeris Biopharma Holdings (XERS) +24%. Griffon Corporation (GFF) +22%. New Concept Energy (GBR) +20%...

Harpoon Therapeutics (NASDAQ:HARP) stock rose ~26% on May 16 after Wedbush upgraded the company's shares to Outperform from Neutral with a price target of $7, up from $5, on model tweaks related to the HPN328 program. Wedbush analyst is awaiting updated data from a phase 1/2 study o...